- Home
- KALV vs PAXS Comparison
KALV vs PAXS Comparison
Compare KALV & PAXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- PAXS
- Stock Information
- Founded
- KALV N/A
- PAXS 2021
- Country
- KALV United States
- PAXS United States
- Employees
- KALV N/A
- PAXS N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- PAXS Investment Managers
- Sector
- KALV Health Care
- PAXS Finance
- Exchange
- KALV Nasdaq
- PAXS Nasdaq
- Market Cap
- KALV 796.4M
- PAXS 723.1M
- IPO Year
- KALV N/A
- PAXS N/A
- Fundamental
- Price
- KALV $13.50
- PAXS $16.04
- Analyst Decision
- KALV Strong Buy
- PAXS
- Analyst Count
- KALV 8
- PAXS 0
- Target Price
- KALV $26.43
- PAXS N/A
- AVG Volume (30 Days)
- KALV 1.0M
- PAXS 195.0K
- Earning Date
- KALV 09-11-2025
- PAXS 01-01-0001
- Dividend Yield
- KALV N/A
- PAXS 11.72%
- EPS Growth
- KALV N/A
- PAXS N/A
- EPS
- KALV N/A
- PAXS N/A
- Revenue
- KALV $1,426,000.00
- PAXS N/A
- Revenue This Year
- KALV N/A
- PAXS N/A
- Revenue Next Year
- KALV $213.43
- PAXS N/A
- P/E Ratio
- KALV N/A
- PAXS N/A
- Revenue Growth
- KALV N/A
- PAXS N/A
- 52 Week Low
- KALV $7.30
- PAXS $12.57
- 52 Week High
- KALV $17.28
- PAXS $15.93
- Technical
- Relative Strength Index (RSI)
- KALV 44.26
- PAXS 54.67
- Support Level
- KALV $13.26
- PAXS $15.46
- Resistance Level
- KALV $17.28
- PAXS $16.46
- Average True Range (ATR)
- KALV 1.03
- PAXS 0.10
- MACD
- KALV -0.10
- PAXS -0.02
- Stochastic Oscillator
- KALV 9.13
- PAXS 27.73
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.